Optimal adherence to highly active antiretroviral therapy (HAART) is crucial to maximize the clinical benefits of treatment, delay disease progression, and to prevent the emergence and transmission of drug-resistant viruses. Although recent data suggest that boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors are more forgiving than nucleoside reverse transcriptase inhibitors and nonboosted protease inhibitors,1,2 adherence at levels of 95% or greater has long been recommended.3 Maintaining long-term adherence to HAART is difficult due to complex regimens, unpleasant side effects, and because patients with HIV infection must take HAART consistently for the duration of their lives. Thus it is critical to identify modifiable factors that impede long-term adherence to HAART.
Depression may be just such a factor. Depression is prevalent among persons with HIV infection and has been linked to suboptimal adherence to HAART. In a nationally representative sample of US women and men with HIV infection participating in the HIV Costs and Services Utilization Study (HCSUS), 36% screened positive for major depression, and 26.5% for dysthymia,4 rates at least 4 times higher than in the general US population. Prevalence estimates of depression in persons with HIV infection vary depending on sample characteristics (eg, demographic characteristics and the percentage with comorbid substance use), assessment technique, and the definition of depression. Depression is also frequently underdiagnosed and untreated in persons with HIV infection5 and in the general population in medical care.6 Some studies have also found that depression is also associated with more rapid disease progression in women and men with HIV infection.7,8
Although many cross-sectional studies have linked depression to suboptimal adherence to HAART,9-12 others did not find an association.13,14 Although several cross-sectional studies and a few longitudinal studies15-18 have found associations between depression and suboptimal adherence, the causal pathways relating depression to poor adherence remain unclear. In particular, few have examined whether onset of depression is associated with poorer adherence to HAART. One study found that an increase in average Center for Epidemiological Studies in Depression (CESD) symptom scores across a 4-month follow-up period was associated with subsequent suboptimal adherence, but baseline depression was not associated with later suboptimal adherence.15 We therefore examined the relationship between the onset of depression symptoms and changes in adherence to HAART in a sociodemographically diverse cohort of persons with HIV in Eastern Massachusetts and Rhode Island.
We used data from the Nutrition for Healthy Living Cohort, a longitudinal observational study investigating the nutritional and clinical status of adult women and men (≥18 years of age) with HIV infection in Boston, MA, and Providence, RI. Participants were invited to take part in the study through newspaper and radio advertisements, and through physician networks in Boston, MA, and Providence, RI. The methods of this study are described in detail elsewhere.19-21 The study protocol received Institutional Review Board approval at Tufts University and the Miriam Hospital. Nutrition for Healthy Living enrolled 881 participants from February 1995 through December 2004, who took part in semiannual study visits. Excluded from the study were those diagnosed with diabetes mellitus, those who were pregnant at time of recruitment, had severe diarrhea, thyroid disease, malignancies other than Kaposi sarcoma, or were not fluent in English.
Because the objective of the current analysis is to determine the relationship of change in depression symptom status to change in adherence to HAART, this study included only participants on HAART who provided adherence information at 4 or more consecutive study visits and met the following additional criteria (n = 225): 4 consecutive study visits in a less than 2.5 year period, on highly active antiretroviral therapy (HAART) and providing adherence information at visits 1 or 2 and 3 or 4 in the 4-visit interval and no depression symptoms at either visits 1 or 2. Participants with missing values for both visit 1 and visit 4 adherence were removed from the subsample. In addition, participants with depression symptoms at any visit before the 4 selected consecutive visits were not included in this analysis.
To assess depression symptoms, we used the Burnam interviewer-administered 8-item screening tool,22 which includes 6 items from the 20-item CESD scale23-26 and 2 items from the Diagnostic Interview Schedule (DIS).27,28 The Burnam screener is a widely used measure29-35 initially developed for inclusion in the Medical Outcomes Study. It uses weighted scoring to maximize the prediction of DSM-III-defined depressive disorder from the 8 items, which are included in Appendix A (Supplemental Digital Content 1, http://links.lww.com/QAI/A13). 36 Although it is a screener which is not sufficient for a clinical diagnosis of depression, it has high sensitivity and specificity for current depression (0.89 and 0.95, respectively).22 As recommended in the original article,22 participants scoring greater than or equal to 0.06 were classified as testing positive for depression symptoms. We classified participants as “developed depression symptoms” or “no depression symptoms,” based on their scores at 4 consecutive visits, which were approximately 6 months apart. We defined participants who developed depression symptoms as having 2 visits with a negative screening test followed by 2 visits with a positive test. Participants in the comparison group (No depression symptoms) were those with 4 consecutive negative depression screening tests.
At each visit, we measured adherence to HAART by first asking participants to identify all of the antiretroviral (ARV) medications that were currently prescribed to them. For each medication, participants reported the number of days over the last 7 days that they had missed a dose of that ARV medication. We then added up across all medications the number of days missed and divided it by the sum of the number of eligible days (7 days for each medication they were prescribed). We calculated suboptimal adherence as the proportion of the 7 days before the study visit that the participant missed a dose of any of his or her prescribed medications. Self-reported suboptimal adherence was defined as missing at least 5% of HAART doses in the 7 days before the study visit. To be eligible for this analysis, participants had to report adherence information at visit 1 or 2 and visit 3 or 4 of the 4 selected consecutive visits. For participants with missing adherence data on the first of their 4 sequential visits, visit 2 adherence was substituted as their baseline adherence. When participants had missing adherence data on the fourth visit of their 4 sequential visits, visit 3 adherence was used.
We examined other demographic (gender, age in years, education level, race/ethnicity, poverty), psychosocial (instrumental social support, current illicit drug use), and clinical (HIV transmission category, HIV viral suppression, CD4 cell count, duration of HAART use, and symptoms) covariates that have been associated with adherence in prior studies.7 Poverty was defined as having a household income less than $10,000 per year. Instrumental social support was measured using indicators from the HCSUS study, which assessed how often people were available to give the respondent money when he or she needed it, and to help with daily chores if he or she was sick.37 We used a 13-item symptom scale similar to that used in the HCSUS study to measure the extent and severity of HIV-related symptoms.38 Participants were asked to endorse whether they experienced any of a list of HIV-related symptoms (eg, severe or persistent headaches, white patches in mouth, painful rashes) and then evaluated on a 5-point scale (ranging from “not at all” to “extremely”) how much each endorsed symptom interfered with their normal activities. We calculated an aggregate symptom score for each participant (ranging from 0 to 100) from the responses. Viral suppression was defined as an HIV-1 RNA count of less than or equal to 400 copies per milliliter.
We conducted all analyses using SAS 9.1 (SAS Institute, Inc, Cary, NC).39 We compared the characteristics at visit 1 of those who subsequently developed depression vs. those who did not develop depression using χ2 tests for categorical variables, t tests for normally distributed continuous variables, and the Kruskal-Wallis test for nonnormally distributed variables. At visits 1 and 4 separately, we compared the proportion nonadherent in those who developed depression vs. the comparison group using the χ2 test. Among those who were adherent at baseline (n = 177), we estimated the relative risk (RR) and 95% confidence intervals (CIs) of nonadherence at follow-up of those who developed depression relative to those who did not using generalized estimating equations with a log link and the binomial distribution.40 Sociodemographic, behavioral, and clinical variables were tested as possible confounders of the relationship between depression and nonadherence. Variables that were associated with suboptimal adherence at P ≤ 0.2 in univariate models were included in multiple regression analyses.
Of the 225 participants eligible for this analysis, 23% were female, 40% were nonwhite, and 89% were high school graduates (Table 1). Sixty-three percent had an undetectable viral load (<400) at the end of the 4-visit interval, and participants had been on HAART for an average of 3.2 years.
Correlates of Developing Depression Symptoms
Among the 225 without depressive symptoms at the first 2 selected visits, 51 (22%) developed depression symptoms at visits 3 and 4 (Table 1). Those who developed depressive symptoms, compared with those without depressive symptoms, were more likely to be women (37% vs. 18%, P = 0.005), have an annual household income of less than $10,000 (58% vs. 36%, P = 0.005), have a baseline CD4 count greater than 500 (46% vs 29% P = 0.05), have higher median symptom scores (18.3 vs. 8.8, P = 0.0001), and lower median levels of instrumental social support (53.1 vs. 80, P = 0.0001).
Rates and Correlates of Suboptimal Adherence
The proportion of participants with suboptimal adherence at baseline (visit 1 or 2) was similar among those who developed depression symptoms and those who did not develop depression symptoms (25.5% and 20.1%, respectively, P = 0.41). In contrast, those who developed depression symptoms were more likely than the comparison group to report suboptimal adherence at follow-up (45.1% vs. 25.9%, P = 0.01) (Fig. 1).
Across the 4-visit period, 137 (61%) were adherent at baseline and follow-up (maintained adherence), 20 (9%) had suboptimal adherence at baseline and became adherent at follow-up, 40 (18%) were adherent at baseline and had suboptimal adherence at follow-up, and 28 (12%) had suboptimal adherence at both baseline and follow-up. Among the 177 adherent at baseline, 34% of those developing depression symptoms had suboptimal adherence at follow-up, compared with 19% of those without depression symptoms (P = 0.05).
The correlates of suboptimal adherence at visit 4 among those who were adherent at visit 1 (n = 177) are shown in Table 2. In univariate analysis, developing depression symptoms was significantly associated with suboptimal adherence at follow-up (RR = 1.7, 95% CI = 1.0 to 3.1). Other variables that were significantly associated with suboptimal adherence included female sex (RR = 2.2; 95% CI = 1.3 to 3.7) and African American race (RR = 2.0, 95% CI = 1.2 to 3.5). Poverty was marginally associated with suboptimal adherence. Age, education, viral load, CD4 count, duration of HAART use, symptom score, instrumental social support, and current drug use were not associated with suboptimal adherence.
In the multivariate model (Table 2), those developing symptoms of depression at follow-up had a nearly 2-fold greater risk of suboptimal adherence at follow-up (RR = 1.8, 95% CI = 1.1 to 3.0), adjusted for gender, race, and income. African American race was a significant independent determinant of developing suboptimal adherence (RR = 1.9, 95% CI = 1.2 to 3.3).
In this longitudinal study of women and men with HIV infection, we found that incident depression symptoms were associated with subsequent suboptimal adherence. We also found a relatively high incidence of depression symptoms. Our finding that 22% of women and men with HIV infection and no previous depression symptoms developed depression symptoms at follow-up is high. It underscores the importance of ongoing screening for and attention to depression among women and men with HIV infection.
This is the first report that we are aware of that examines the effect of incident depression symptoms on adherence in persons with HIV. Spire et al15 found that a change in median CESD scores over a 4-month period was associated with nonadherence over the same period; but because they measured changes in CESD scores, it is not possible to know how many people at each time point had major depression. In a study of men in the Multicenter AIDS Cohort Study, depression at the start of a 6-month interval was associated with a decline in adherence over the subsequent 6 months, but it was not true that the absence of depression was associated with improved adherence.17 Carrieri et al16 found that baseline depression was associated with an inability to maintain adherence at 18 months follow-up in a cohort of injection drug users initially adherent to ARV treatment in France. Our study extends the findings of these previous longitudinal studies by demonstrating that onset of depression symptoms is associated with increasing rates of suboptimal adherence.
A meta-analysis of depression and adherence to medical care regimens in general (not only HIV ARVs) found that patients with depression had a 3-fold higher odds of poor adherence and suggested possible mechanisms linking depression to poor adherence to medical treatments.41 Included in these possible mechanisms were the feeling of hopelessness which often accompanies depression, social isolation, and an absence of social support.15 Any or all of these mechanisms may be operative in individuals with HIV infection. It has been shown that the presence of social support and other psychosocial resources have been associated with increased survival in women with HIV infection;42 improved survival may be a result of improved adherence.
African Americans in our study had a higher risk of decline in adherence over time compared with whites. In contrast, Kleeberger et al17 found that African American race was not associated with a decline in adherence among those with perfect adherence, but did predict continued suboptimal adherence among patients who already had poor adherence, whereas white race predicted later improvements in adherence in those with poor adherence. Some cross-sectional studies have identified an association between African American race and suboptimal adherence to HAART and others have not.9 Although several studies have highlighted this association, further research is needed to identify the mechanisms by which race and adherence may be related. Studies investigating racial disparities in health care have identified patient-level factors including lack of trust in health care providers and the health care system; provider-level factors, including unfair treatment, discrimination,43 or other aspects of the quality of the doctor-patient relationship; and structural factors (eg, inadequate access to or lower quality of care) which could contribute to racial disparities in adherence. It could also be that unmeasured variables such as skepticism about the efficacy of ARVs or distrust in the provider or health care system contribute to the findings we observed.
A strength of this study is our stringent criteria for classification of depression based on 2 visits without depression symptoms followed by 2 visits with depression symptoms, which makes it more possible to establish a clear temporal relationship between depression symptoms and changes in adherence. There are some study limitations. First, we assessed adherence to HAART through participant self-report, so rates of adherence may be overestimates.44,45 Second, the conservative cutoff we used for depression symptoms, which required screening positive for depression symptoms at 2 consecutive visits, may have missed some people who may have had diagnosable depression at just 1 visit. Third, this study did not include all possible profiles of depression symptom transitions over the 4 study visits. For example, participants who reported depression symptoms at all 4 visits were not included in this analysis. The effects of chronic depression are likely different from those of incident depression. Fourth, although it is possible that prior poor adherence contributed to onset of depression symptoms, which in turn contributed to worse adherence, this is clinically unlikely. Furthermore, visit 1 nonadherence was not associated with subsequent development of depression symptoms. Finally, it was not possible to analyze the contribution of treatment for depressive symptoms to adherence outcomes.
The results from this study highlight that in persons with HIV infection, the relationship of depressive symptoms to HAART adherence is dynamic rather than static. Our finding that depression symptom onset is associated with a change to suboptimal adherence supports the need for further research to evaluate the impact of treatment for depression on adherence to HAART. Depression can be effectively treated with medications in patients with HIV infection.46 Some studies have found that mental health therapy with and without antidepressant medication leads to an increase in HAART utilization in women with HIV infection.47 In addition, some studies have demonstrated the effectiveness of cognitive behavioral therapy in improving adherence.46,48,49 Further research is needed to evaluate the impact of psychosocial and pharmacological treatment interventions for depression on clinical outcomes in patients with HIV and to identify interventions that prevent worsening adherence or improve adherence over time.
The results from this study also underscore the importance of ongoing aggressive screening for depression to intervene to improve mental health and HAART adherence in patients with HIV infection. For screening to be cost effective and have an impact, it is critical to strengthen referral systems to ensure appropriate treatment of and follow-up for depression for patients with HIV and depression not only because it may improve adherence and HAART outcomes but also because of its potential impact on quality of life overall.
The authors wish to thank James Fauntleroy and Sally Skinner for SAS programming advice and support; and the women and men who participated in the Nutrition for Healthy Living Study, and the Nutrition for Healthy Living research team for their valuable contributions.
1. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence
-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS
2. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence
to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI- or PI-treated patients. HIV Clin Trials
3. Paterson DL, Swindells S, Mohr J, et al. Adherence
to protease inhibitor therapy and outcomes in patients with HIV
infection. Ann Intern Med
4. Bing EG, Burnam AM, Longshore D, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. Arch Gen Psychiatry
5. Asch SM, Kilbourne AM, Gifford AL, et al; for the HCSUS Consortium. Underdiagnosis of depression
: who are we missing? J Gen Intern Med
6. Schulberg HC, Block MR, Madonia MJ, et al. The usual care of major depression
in primary care practice. Arch Fam Med
7. Ickovics JR, Hamburger ME, Vlahov D, et al. Mortality, CD4 cell count decline, and depressive symptoms among HIV
-seropositive women. JAMA
8. Ironson G, O'Cleirigh C, Fletcher MA, et al. Psychosocial factors predict CD4 and viral load change in men and women with human immunodeficiency virus in the era of highly active antiretroviral treatment. Psychosom Med
9. Ammassari A, Antinori A, Aloisi MS, et al. Depressive symptoms, neurocognitive impairment, and adherence
to highly active antiretroviral therapy
-infected persons. Psychosomatics
10. Gonzalez JS, Penedo FJ, Antoni MH, et al. Social support, positive status of mind, and HIV
in men and women living with HIV
/AIDS. Health Psychol
11. Schuman P, Ohmit SE, Cohen M, et al. Prescription of and adherence
to antiretroviral therapy
among women with AIDS. AIDS Behav
12. Gordillo V, del Amo J, Soriano V, et al. Sociodemographic and psychologic variables influencing adherence
to antiretroviral therapy
13. Turner BJ, Laine C, Cosler L, et al. Relationship of gender, depression
, and health care delivery with antiretroviral adherence
-infected drug users. J Gen Intern Med
14. Stone VE, Hogan JW, Schuman P, et al. Antiretroviral regimen complexity, self-reported adherence
, and HIV
patients' understanding of their regimens: survey of women in the HER study. J Acquir Immune Defic Syndr
15. Spire B, Duran S, Souville M, et al; the APROCO cohort study group. Adherence
to highly active antiretroviral therapies (HAART) in HIV
-infected patients: from a predictive to a dynamic approach. Soc Sci Med
16. Carrieri MP, Chesney MA, Spire B, et al; the MANIF Study Group. Failure to maintain adherence
to HAART in a cohort of French HIV
-positive injecting drug users. Int J Behav Med
17. Kleeberger CA, Buechner J, Pelella F, et al. Changes in adherence
to highly active antiretroviral therapy
medications in the multicenter AIDS Cohort Study. AIDS
18. Murphy DA, Belzer M, Durako SJ, et al; Adolescent Medicine HIV
/AIDS Research network. Longitudinal antiretroviral adherence
among adolescents infected with human immunodeficiency virus. Arch Pediatr Adolesc Med
19. Wilson IB, Roubenoff R, Knox TA, et al. Relation of lean body mass to health-related quality of life in persons with HIV
. J Acquir Immune Defic Syndr
20. Shevitz AH, Knox TA, Spiegelman D, et al. Elevated resting energy expenditure among HIV
-seropositive persons receiving highly active antiretroviral therapy
21. Silva M, Skolnick P, Gorbach S, et al. The effect of protease inhibitors on weight and body composition in HIV
-infected patients. AIDS
22. Burnam MA, Wells KB, Leake B, et al. Development of a brief screening instrument for detecting depressive disorders. Med Care
23. Radloff LN. The CES-D scale: a self-report depression
scale for research in the general population. Appl Psychol Meas
24. Weissman MM, Sholomskas D, Pottenger M, et al. Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol
25. Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression
in a community sample. Am J Psychiatry
26. Weissman MM, Pilowsky DJ, Wickramaratne PJ, et al. Remissions in maternal depression
and child psychopathology: a START*D-child report. JAMA
27. Robins LN, Helzer JE, Ratcliff KS, et al. Validity of the diagnostic interview schedule, version II:DSM-II diagnoses. Psychol Med
28. Robins LN, Helzer JE, Croughan J, et al. National Institute of Mental Health Diagnostic Interview Schedule. Its history, characteristics, and validity. Arch Gen Psychiatry
29. Sherman AM. Social relations and depressive symptoms in older adults with knee osteoarthritis. Soc Sci Med
30. Ahluwalia JS, Richter K, Mayo MS, et al. African American smokers interested and eligible for a smoking cessation clinical trial: predictors of not returning for randomization. Ann Epidemiol
31. Hlatky MA, Boothroyd D, Vittinghoff E, et al. Quality of life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA
32. Katz DA, McHorney CA. The relationship between insomnia and health-related quality of life in patients with chronic illness. J Fam Pract
33. Foy CG, Wickley KL, Adair N, et al. The reconditioning exercise and chronic obstructive pulmonary disease trial II (REACT II): rationale and study design for a clinical trial of physical activity among individuals with chronic obstructive pulmonary disease. Contemp Clin Trials
34. Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women's Health Initiative Observational Study. J Am Geriatr Soc
35. Sivarajan Froelicher ES, Miller NH, Chritopherson DJ, et al. High rates of sustained smoking cessation in women hospitalized with cardiovascular disease: the Women's Initiative for Nonsmoking (WINS). Circulation
36. Isaac R, Jacobson D, Wanke C, et al. Declines in dietary macronutrient intake in persons with HIV
who develop depression
. Public Health Nutr
37. Crystal S, Akincigil A, Sambamoorthi U, et al. The diverse older HIV
-positive population: a national profile of economic circumstances, social support, and quality of life. J Acquir Immune Defic Syndr
38. Hays RD, Spritzer KL, McCaffrey D, et al. The HIV Cost and Services Utilization Study (HCSUS) Measures of Health-Related Quality of Life
. Santa Monica, CA: RAND; 1998. DRU-1997-AHCPR.
39. Copyright SAS Institute Inc, Cary, NC.
40. Spiegelman D, Hertzmark E. Easy SAS calculations for risk or prevalence ratios and differences. Am J Epidemiol
41. DiMatteo MR, Lepper HS, Croghan TW. Depression
is a risk factor for non-compliance with medical treatment: meta-analysis of the effects of anxiety and depression
on patient adherence
. Arch Intern Med
42. Ickovics J, Milan S, Boland R, et al; for the HERS Study Group. Psychological resources protect health: 5-year survival and immune function among HIV
-infected women from four US cities. AIDS
43. Bird ST, Bogart LM, Delahunty DL. Health-related correlates of perceived discrimination in HIV
care. AIDS Patient Care STDs
44. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence
and viral suppression in HIV
-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis
45. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence
protease inhibitors. Ann Intern Med
46. Olatunji BO, Mimiaga MJ, O'Cleirigh C, et al. A review of treatment studies of depression
. Top HIV Med
47. Cook JA, Grey D, Burke-Miller J, et al. Effects of treated and untreated depressive symptoms on highly active antiretroviral therapy
use in a US multi-site cohort of HIV
-positive women. AIDS Care
48. Safren S, Hendriksen E, Mayer K, et al. Cognitive behavioral therapy for HIV
. Cogn Behav Pract
49. Safren SA, O'Cleirigh C, Tan JY, et al. A randomized controlled trial of cognitive behavioral therapy for adherence
(CBT-AD) in HIV
-infected individuals. Health Psychol
APPENDIX A: Burnam Depression Screener Items
- 1. In the past year, have you had 2 weeks or more during which you felt sad, blue, or depressed; or when you lost all interest or pleasure in things that you usually cared about or enjoyed? (1 = yes/0 = no)
- 2. Have you had 2 years or more in your life when you felt depressed or sad most days, even if you felt okay sometimes? (1 = yes/0 = no) If not go to question 3.
- a. Have you felt depressed or sad much of the time in the past year? (1= yes/0 = no).
- 3. For each statement below, mark one circle that best describes how much of the time you felt or behaved this way during the past week. Response options are:
- 0: Rarely or None of the time (less than one day)
- 1: Some or a little of the time (1-2 days).
- 2: Occasionally or moderate amount of the time (3-4 days).
- 3: Most or all of the time (5-7 days).
- During the past week:
- a. I felt depressed.
- b. I had crying spells.
- c. I felt sad.
- d. I enjoyed life (reverse scoring).
- e. My sleep was restless.
- f. I felt that people disliked me.
The first 2 items are from the Diagnostic Interview Schedule and are most strongly related to the criterion measure, the full Diagnostic Interview Schedule.